Guideline‑Based Evaluation of COPD Patients (GOLD)

1. Diagnostic Criteria

• COPD is diagnosed when a post‑bronchodilator FEV₁/FVC < 0.70 is observed in a patient who is symptomatic and has a significant exposure history (e.g., ≥10 pack‑years smoking, occupational dusts, biomass fuel). This definition is endorsed by the Global Initiative for Chronic Obstructive Lung Disease (GOLD). 1
• The diagnosis requires the essential triad: (1) post‑bronchodilator spirometry showing the fixed ratio abnormality, (2) presence of typical symptoms (dyspnea, chronic cough, sputum, wheeze, chest tightness), and (3) a relevant exposure (smoking, occupational, or biomass). 2

2. Spirometry Protocol

• Post‑bronchodilator testing must always be performed; relying on pre‑bronchodilator values misses volume responders in ~3 % of cases and over‑diagnoses COPD in flow responders in 11‑17 % of cases. 3
• When the initial post‑bronchodilator FEV₁/FVC falls between 0.60 – 0.80, repeat spirometry after 3–6 months on a separate occasion to account for biological variability and improve diagnostic specificity. 3 [2]
• If the initial post‑bronchodilator FEV₁/FVC is < 0.60, repeat testing is unnecessary because spontaneous rise above the 0.70 threshold is exceedingly unlikely. 3
• The fixed ratio may over‑diagnose COPD in patients > 70 years and under‑diagnose it in those < 45 years; nevertheless, GOLD continues to recommend the 0.70 cutoff for its simplicity and consistency across trials. 1 [2]

3. Spirometric Grading (Epidemiologic Use)

• GOLD stages based on post‑bronchodilator FEV₁ % predicted:
  
  • GOLD 1 (Mild): ≥ 80 %
  • GOLD 2 (Moderate): 50‑79 %
  • GOLD 3 (Severe): 30‑49 %
  • GOLD 4 (Very Severe): < 30 %
  • (These grades are retained for research and disease‑burden description but do not guide treatment decisions per the 2017 GOLD revision.) 1 [2]

4. Comprehensive Medical History

• Exposure assessment – document smoking pack‑years, occupational dust/chemical exposure, and biomass or ambient air pollution. 1 [2]
• Symptom characterization – dyspnea (most characteristic), cough (often first symptom), sputum volume (large volumes may suggest bronchiectasis), wheeze/chest tightness variability, and systemic features (fatigue, weight loss, anorexia). All are highlighted by GOLD. 1
• Disease impact – record exacerbation frequency/severity, functional limitation (activity restriction, work absenteeism), and psychological burden (depression, anxiety). 1
• Comorbidity screening – systematically evaluate cardiovascular disease (leading cause of death in COPD), lung cancer (third leading cause), osteoporosis, and mood disorders. These comorbidities independently affect mortality and hospitalisation. 1 [2]

5. Physical Examination Findings

• Hyperinflation signs – barrel chest, reduced chest expansion, hyperresonance. 1
• Airflow‑limitation signs – prolonged expiratory phase, wheeze, pursed‑lip breathing. 2
• Cor pulmonale signs – elevated jugular venous pressure, peripheral edema, hepatomegaly (seen in severe disease). 4
• Cachexia/muscle wasting – indicative of advanced disease. 1

6. Multidimensional Prognostic Assessment

• BODE index (validated for moderate‑to‑severe COPD):
  
  • B – Body‑mass index < 21 kg/m² predicts higher mortality. 1
  • O, D, E – obstruction (FEV₁ % pred), dyspnea (mMRC), exercise capacity (6‑min walk).
• BODE score interpretation – 5‑6 points = severe COPD; ≥ 7 points = very severe COPD. 4

7. Phenotype Recognition

• Chronic bronchitis phenotype – defined by a productive cough lasting ≥ 3 months in ≥ 2 consecutive years. 1
• Asthma‑COPD overlap (ACO) – patients exhibit features of both asthma and COPD and require inhaled corticosteroid‑containing regimens. 5

8. Indications for Specialist Referral (Pulmonology)

• Diagnostic uncertainty or symptoms disproportionate to spirometric findings. 4
• Suspected severe COPD needing optimisation of therapy. 4
• Development of cor pulmonale. 4
• Assessment for long‑term oxygen therapy (arterial blood‑gas analysis). 4
• Rapid FEV₁ decline or COPD onset < 40 years (consider α₁‑antitrypsin deficiency). 4
• Presence of bullous disease (potential surgical candidate). 4
• Frequent respiratory infections (to exclude bronchiectasis). 1

9. Recommended Evaluation Algorithm (GOLD)

GOLD COPD Assessment and Classification

Multidimensional GOLD Classification Framework

• The Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends a multidimensional approach that integrates post‑bronchodilator spirometric grading, symptom burden (mMRC or CAT), and exacerbation history to assign patients to ABCD groups that guide therapy. 6

Spirometric Grading (GOLD 1‑4)

• Post‑bronchodilator spirometry is required; airflow obstruction is defined by FEV₁/FVC < 0.7. Severity is then graded by post‑bronchodilator FEV₁ % predicted:

Symptom Assessment Thresholds

• mMRC dyspnea scale: a score of ≥ 2 defines “high symptoms.” 6
• COPD Assessment Test (CAT): a total score of ≥ 10 defines “high symptoms.” 7

Exacerbation Risk Definition

• A patient is considered at high exacerbation risk when either:

ABCD Assessment Groups (Treatment‑Guiding Classification)

• Group A: Low symptoms (mMRC 0‑1 or CAT < 10) and low exacerbation risk (0‑1 events, no hospitalizations).
• Group B: High symptoms (mMRC ≥ 2 or CAT ≥ 10) and low exacerbation risk.
• Group C: Low symptoms and high exacerbation risk (≥ 2 moderate or ≥ 1 severe event).
• Group D: High symptoms and high exacerbation risk.

Multidimensional Prognostic Indices

BODE Index (most validated)

• BODE score interpretation: 0‑2 = mild, 3‑4 = moderate, 5‑6 = severe, ≥ 7 = very severe COPD. 8

BODEx Index (alternative when exercise testing unavailable)

• Replaces the exercise component with exacerbation history; recommended for patients in GOLD stages I‑II. 7

Recommended Clinical Assessment Algorithm (GOLD)

Impact of Comorbidities

• Systematic assessment of comorbid conditions (e.g., cardiovascular disease, osteoporosis, depression) is essential because they markedly influence disease severity, prognosis, and treatment outcomes in COPD. 9